| Product Name | Tozasertib(VX-680;MK-0457) |
|---|---|
| CAS | 639089-54-6 |
| Formula | C23H28N8OS |
| MW | 464.59 |
| Appearance | White to off-white powder |
| Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 25 mg | In-stock | ¥350.00 | Visible after login | |
| 50 mg | In-stock | ¥550.00 | Visible after login | |
| 100 mg | In-stock | ¥860.00 | Visible after login | |
| 500 mg | In-stock | ¥2800.00 | Visible after login |
| Product Name | Tozasertib(VX-680;MK-0457) |
|---|---|
| CAS | 639089-54-6 |
| Formula | C23H28N8OS |
| MW | 464.59 |
| Appearance | White to off-white powder |
| Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Tozasertib (VX-680) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and BCR-ABL tyrosine kinase, which are inhibited by the Tozasertib with both Ki of 30 nM. Tozasertib induces apoptosis and autophagy.